Variable | aNSCLC patients | Mutation positive aNSCLC patients | |
---|---|---|---|
Based on a 12-month follow-up: | N1 | 1741 | 122 |
No systemic treatment | % of patients | 5·34% | 6·56% |
1 L treatment only | % of patients | 68·81% | 37·70% |
1 L + 2 L treatment | % of patients | 19·47% | 38·52% |
1 L + 2 L + 3 L treatment | % of patients | 5·17% | 13·93% |
1 L + 2 L + 3 L+ further line of treatment | % of patients | 1·21% | 3·28% |
Based on a 24-month follow-up: | N1 | 1433 | 106 |
No systemic treatment | % of patients | 4·54% | 3·77% |
1 L treatment only | % of patients | 60·29% | 16·98% |
1 L + 2 L treatment | % of patients | 22·40% | 36·79% |
1 L + 2 L + 3 L treatment | % of patients | 8·79% | 24·53% |
1 L + 2 L + 3 L+ further line of treatment | % of patients | 3·98% | 17·92% |
Based on a 36-month follow-up: | N1 | 1009 | 75 |
No systemic treatment | % of patients | 3·87% | 4·00% |
1 L treatment only | % of patients | 58·97% | 16·00% |
1 L + 2 L treatment | % of patients | 22·30% | 29·33% |
1 L + 2 L + 3 L treatment | % of patients | 9·71% | 20·00% |
1 L + 2 L + 3 L+ further line of treatment | % of patients | 5·15% | 30·67% |